Avidity Biosciences, Inc.
Avidity Biosciences is a clinical-stage biopharmaceutical company built around its proprietary Antibody Oligonucleotide Conjugate, or AOC, platform. The company is developing a pipeline of RNA-based medicines designed to deliver oligonucleotide therapies to specific tissues, with a current focus on rare neuromuscular diseases and precision cardiology. Its lead programs include del-desiran, del-brax, and del-zota, which are being advanced toward potential commercialization. Avidity has not yet commercialized a product and has funded its operations primarily through equity financings and collaboration agreements.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAntibody Oligonucleotide Conjugate technology used to deliver RNA therapeutics to specific tissues and cell types.
Lead programs in clinical development, including del-desiran, del-brax, and del-zota.
Earlier-stage programs in neuromuscular, precision cardiology, and other tissue types.
Upfront, milestone, and service reimbursement revenue from research and license agreements.
Customers
Avidity does not yet sell approved products, so its current counterparties are collaboration partners rather than end-market patients or hospitals. Revenue to date has come from license and research collaboration agreements, including upfront payments, milestone payments, and reimbursements for services. If its programs are approved, the company expects to serve patients with rare neuromuscular diseases and potentially precision cardiology indications through commercial channels it would need to build or outsource. The company also relies heavily on CROs, CMOs, consultants, and scientific advisors to conduct research, manufacturing, and clinical development.
Partners that provide upfront fees, milestones, and research reimbursements for AOC programs and may help advance non-core indications.
Future end users for approved therapies such as del-desiran, del-brax, and del-zota, where the company aims to address high unmet need.
Neuromuscular and cardiology specialists who would diagnose, prescribe, and monitor therapy if products are commercialized.
External service providers that support preclinical studies, clinical trials, and manufacturing of product candidates.
Third parties with established sales and distribution capabilities that could commercialize products in selected geographies or indications.
Strategy
Avidity's strategy is centered on proving the AOC platform and advancing its lead clinical programs in rare neuromuscular disease while expanding into precision cardiology and other tissue types. Management has emphasized retaining development and commercialization rights where it believes it can successfully launch products itself, while partnering in areas better served by external expertise. The company is also building global commercial infrastructure in anticipation of potential successive launches starting in 2026. Longer term, it aims to extend the platform beyond muscle into additional tissues and indications through internal research and collaborations.
Clinical success is the main value driver because the company has no approved products or product sales yet.
The company needs sales, marketing, distribution, and launch capabilities if its first products are approved.
Broader tissue delivery could create a larger pipeline and reduce dependence on a small number of programs.
As a development-stage biotech, funding needs are high and partnerships can reduce risk and extend runway.
Geography
Avidity is headquartered in San Diego, California and operates as a U.S.-based biotechnology company. The filings do not disclose a meaningful country-level revenue mix because the company has not commercialized products and its revenue comes from collaboration agreements. Its development and future commercialization plans are global in scope, with management noting that it may retain rights in geographies it can commercialize itself and collaborate in others. Geography matters mainly through regulatory pathways, clinical trial execution, manufacturing logistics, and the need to build or partner for market access in major regions.
Risks
Avidity faces the classic risks of a clinical-stage biotech: uncertain clinical outcomes, regulatory risk, and the possibility that its platform never produces commercially viable products. The company has a limited operating history, significant accumulated losses, and expects continued cash burn as it funds trials, manufacturing, and platform expansion. It also depends on third parties for clinical execution and manufacturing, which creates operational and quality-control risk. In addition, the pending Novartis merger introduces transaction-completion risk, while competition, intellectual property protection, and healthcare pricing/reimbursement pressures remain material industry-wide threats.
- Clinical development failureImpact: CriticalLikelihood: Medium
The company has three product candidates in clinical development and all other programs are preclinical or discovery-stage, so pipeline value depends on successful trials and approvals.
Exposure - Capital requirements and financing riskImpact: HighLikelihood: High
Avidity has incurred significant operating losses since inception and expects continued losses, so it may need additional funding to sustain development and launch plans.
Exposure: Company-wide
- Third-party execution riskImpact: HighLikelihood: Medium
The company relies on CROs, CMOs, consultants, and scientific advisors for development and manufacturing, which can affect timelines, quality, and cost.
Exposure: Clinical and manufacturing operations
- Competition and IP riskImpact: HighLikelihood: Medium
Biopharma competition is intense and the company must protect its AOC platform and candidate-specific intellectual property to preserve value.
Exposure: Platform and pipeline
- Merger completion riskImpact: MediumLikelihood: Medium
The pending Novartis transaction may not close on the anticipated timeline or at all, which could disrupt operations and investor expectations.
Exposure: Corporate transaction
Accounting
Judgemental itemsRevenue comes from license and research agreements, so management must estimate timing and allocation of upfront, milestone, and service payments.
Impact: Can materially affect quarterly revenue and comparability
A large share of R&D is outsourced, requiring estimates for services received but not yet invoiced.
Impact: Affects R&D expense and liabilities
Equity awards are used to attract and retain employees in a competitive biotech labor market.
Impact: Raises operating expenses and reported net loss
Milestone timing and service reimbursements are inherently uneven.
Impact: Makes period-to-period comparisons difficult
Similar listed companies
Publicly listed companies with a comparable business focus.
Ovid Therapeutics Inc.
OVID · Pharmaceutical Preparations
Oddity Tech Ltd
ODD · Perfumes, Cosmetics & Other Toilet Preparations
Oddity Tech Ltd is a U.S.-based consumer technology company that builds and scales digital-first beauty and wellness brands through an AI-driven online platform.
iBio, Inc.
IBIO · Pharmaceutical Preparations
Benitec Biopharma Inc.
BNTC · Pharmaceutical Preparations
Assembly Biosciences, Inc
ASMB · Pharmaceutical Preparations
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026